This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog OutTherapy AreasProductsOrder VaccinesOrder SamplesOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact
Search
Menu
Close
AboutDosing & MonitoringDosing & MonitoringDosing and administrationMonitoringRecommended dose modificationsIBRANCE tablets and capsulesClinical Trial DataClinical Trial DataIBR + AI Efficacy & SafetyIBR + AI Additional AnalysesIBR + Fulvestrant Efficacy & SafetyIBR + Fulvestrant Additional AnalysesAdditional DataAdditional DataRCTs and RWESelect data and publicationsLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkVideosPatient SupportPatient SupportPerspectives for your patientsResources for your patientsCoverage and accessMaterials
Prescribing Information for CapsulesPrescribing Information for Tablets Indications Patient Site
Patient SupportCoverage and access

Pfizer is committed to supporting your patients throughout their treatment journey. With Pfizer Oncology Together, patients prescribed IBRANCE get personalized support, including help identifying financial assistance options.

Commercially insured

Resources for eligible patients with commercial, private, employer, or state health insurance marketplace coverage

Co-pay assistance

Eligible, commercially insured patients may pay as little as $0 per month for their Pfizer Oncology treatment. Limits, terms, and conditions apply.* Patients may receive up to $4,000-$10,000 in savings annually.

 Get the card now LoadingReferencesPatients are not eligible to use this card if they are enrolled in a state or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veterans Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico.Medicare/government insured

Help identifying resources for patients with Medicare/Medicare Part D, Medicaid, and other government insurance plans who express a financial need and may be eligible:

  • We can assist patients with searching for financial support from alternate funding resources, which may include financial assistance through Extra Help, a Medicare Part D Low-Income Subsidy (LIS) program

  • If support from alternate funding resources or Medicare Extra Help is not available, Pfizer Oncology Together will see if your patient is eligible for the Pfizer Patient Assistance Program,† which can provide prescribed Pfizer Oncology medications for free

Uninsured

Help identifying resources for patients without any form of healthcare coverage who may be eligible:

  • We can check patient eligibility for Medicaid and help them understand how to apply

  • Patients who do not qualify for Medicaid may receive free medication through the Pfizer Patient Assistance Program† or at a savings through the Pfizer Savings Program.‡ Patients must be eligible and reapply as needed

ReferencesThe Pfizer Patient Assistance Program is a joint program of Pfizer Inc. and the Pfizer Patient Assistance Foundation™. The Pfizer Patient Assistance Foundation is a separate legal entity from Pfizer Inc. with distinct legal restrictions.The Pfizer Savings Program is not health insurance. For more information, call the toll-free number 1-877-744-5675. There are no membership fees to participate in this program. Estimated savings are 50% and depend on such factors as the particular drug purchased, amount purchased, and the pharmacy where purchased.Access and reimbursement support

If patients need access or reimbursement assistance, Pfizer Oncology Together is here to help with:

We can help determine a patient's coverage and out-of-pocket costs.We can coordinate with a patient’s insurer to determine the PA requirements. After your office submits a PA request, we can follow up with the payer until a final outcome is determined.We can review the reasons for a denied claim and provide information on payer requirements. After your office submits an appeal, we can follow up with the payer until a final outcome is determined.Free trial voucherFree 1-month (21-day) trial is available for new patients

Pfizer is committed to helping your eligible patients get started on IBRANCE.

  • To get patients started with a trial voucher, call 1-877-744-5675 or speak with your local IBRANCE representative§
  • To obtain free samples, speak with your local IBRANCE representative||
ReferencesLimits, terms, and conditions apply. Please see below.Available at 125 mg, 100 mg, or 75 mg doses.Voucher eligibility criteria

This 1-month (21-day) voucher is not a prescription for IBRANCE.

To continue a patient on therapy, a separate prescription must be written to be filled at a participating pharmacy.

TERMS AND CONDITIONS

By redeeming this voucher, you acknowledge that you currently meet the eligibility criteria and will comply with the terms and conditions described below:

  1. You will receive a 1-month (21-day) supply of IBRANCE.
  2. The voucher is valid for one 21-day trial. Patients may be eligible for one additional 21-day period if a dose adjustment is needed. Only new IBRANCE patients and patients receiving one dose adjustment within 90 days after initiation of treatment are eligible to use this voucher.
  3. By redeeming this voucher, you certify that you are either not currently taking IBRANCE or, if you are taking IBRANCE, that you have been prescribed one dose adjustment within 90 days of initiating IBRANCE treatment.
  4. If you would like to redeem this voucher due to a dose adjustment, please contact Pfizer Oncology Together (1-877-744-5675), and they will determine eligibility and assist with the activation process of your additional voucher.
  5. An original voucher and a valid prescription must be presented to the pharmacy.
  6. This voucher will be accepted only at participating pharmacies.
  7. You must not submit any claim for reimbursement for product dispensed pursuant to this voucher to any third-party payer, including Medicare, Medicaid, or any other federal or state health care program. You cannot apply the value of the free product received through this voucher toward any government insurance benefit out-of-pocket spending calculations, such as Medicare Part D True Out-of-Pocket Costs (TrOOP).
  8. You must be 18 years of age or older to redeem this voucher.
  9. This voucher is not valid for Massachusetts residents whose prescriptions are covered in whole or in part by third-party insurance.
  10. This voucher is not valid where prohibited by law.
  11. This voucher cannot be combined with any other savings, free trial, or similar offer for the specified prescription. This voucher should not be combined with samples for the specified prescription.
  12. This free trial voucher is not health insurance. This free trial voucher is not intended to address delays or gaps in health insurance coverage for the specified prescription.
  13. Offer good only in the United States and Puerto Rico.
  14. No purchase is necessary.
  15. No membership fees.
  16. Patients have no obligation to continue to use IBRANCE.
  17. Pfizer reserves the right to rescind, revoke, or amend this offer without notice.
  18. This voucher expires 12/31/2025.
  19. For questions, please call Pfizer Oncology Together at 1-877-744-5675 or visit PfizerOncologyTogether.com.
Specialty pharmacy coordinationWe can identify specialty pharmacy options

To help your patients access the medication you’ve prescribed, we can identify specialty pharmacy options. If you prefer, you and your staff can also continue to work directly with specialty pharmacies.

 See pharmacies in network LoadingPatient Support Dedicated local support

Pfizer Oncology Account Specialists can provide detailed information on Pfizer Oncology medications and access resources. In addition, they can help you and your office staff contact a Pfizer Field Reimbursement Manager (FRM) in your area.

FRMs are trained to help address specific access issues—in person or over the phone. 

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2025 Pfizer Inc. All rights reserved.

PP-IBR-USA-6615
You are now leaving PfizerPro You are now leaving a Pfizer-operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.PP-MCL-USA-0367
INDICATIONS IBRANCE® (palbociclib) 125 mg capsules and tablets are indicated for the treatment of adult patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer (mBC) in combination with:
 
  • an aromatase inhibitor as initial endocrine-based therapy, or
  • fulvestrant in patients with disease progression following endocrine therapy.
IMPORTANT SAFETY INFORMATIONNeutropenia was the most frequently reported adverse reaction in PALOMA-2 (80%) and PALOMA-3 (83%). In PALOMA-2, Grade 3 (56%) or 4 (10%) decreased neutrophil counts were reported in patients receiving IBRANCE plus letrozole. In PALOMA-3, Grade 3 (55%) or Grade 4 (11%) decreased neutrophil counts were reported in patients receiving IBRANCE plus fulvestrant. Febrile neutropenia has been reported in 1.8% of patients exposed to IBRANCE across PALOMA-2 and PALOMA-3. One death due to neutropenic sepsis was observed in PALOMA-3. Inform patients to promptly report any fever. 
Monitor complete blood count prior to starting IBRANCE, at the beginning of each cycle, on Day 15 of first 2 cycles and as clinically indicated. Dose interruption, dose reduction, or delay in starting treatment cycles is recommended for patients who develop Grade 3 or 4 neutropenia. 

Severe, life-threatening, or fatal interstitial lung disease (ILD) and/or pneumonitis can occur in patients treated with CDK4/6 inhibitors, including IBRANCE when taken in combination with endocrine therapy. Across clinical trials (PALOMA-1, PALOMA-2, PALOMA-3), 1% of IBRANCE-treated patients had ILD/pneumonitis of any grade, 0.1% had Grade 3 or 4, and no fatal cases were reported. Additional cases of ILD/pneumonitis have been observed in the post-marketing setting, with fatalities reported. 

Monitor patients for pulmonary symptoms indicative of ILD/pneumonitis (e.g., hypoxia, cough, dyspnea). In patients who have new or worsening respiratory symptoms and are suspected to have developed pneumonitis, interrupt IBRANCE immediately and evaluate the patient. Permanently discontinue IBRANCE in patients with severe ILD or pneumonitis. 

Based on the mechanism of action, IBRANCE can cause fetal harm. Advise females of reproductive potential to use effective contraception during IBRANCE treatment and for at least 3 weeks after the last dose. IBRANCE may impair fertility in males and has the potential to cause genotoxicity. Advise male patients to consider sperm preservation before taking IBRANCE. Advise male patients with female partners of reproductive potential to use effective contraception during IBRANCE treatment and for 3 months after the last dose. Advise females to inform their healthcare provider of a known or suspected pregnancy. Advise women not to breastfeed during IBRANCE treatment and for 3 weeks after the last dose because of the potential for serious adverse reactions in nursing infants. 

The most common adverse reactions (≥10%) of any grade reported in PALOMA-2 for IBRANCE plus letrozole vs placebo plus letrozole were neutropenia (80% vs 6%), infections (60% vs 42%), leukopenia (39% vs 2%), fatigue (37% vs 28%), nausea (35% vs 26%), alopecia (33% vs 16%), stomatitis (30% vs 14%), diarrhea (26% vs 19%), anemia (24% vs 9%), rash (18% vs 12%), asthenia (17% vs 12%), thrombocytopenia (16% vs 1%), vomiting (16% vs 17%), decreased appetite (15% vs 9%), dry skin (12% vs 6%), pyrexia (12% vs 9%), and dysgeusia (10% vs 5%).

The most frequently reported Grade ≥3 adverse reactions (≥5%) in PALOMA-2 for IBRANCE plus letrozole vs placebo plus letrozole were neutropenia (66% vs 2%), leukopenia (25% vs 0%), infections (7% vs 3%), and anemia (5% vs 2%). 

Lab abnormalities of any grade occurring in PALOMA-2 for IBRANCE plus letrozole vs placebo plus letrozole were decreased WBC (97% vs 25%), increased blood creatinine (96% vs 91%), decreased neutrophils (95% vs 20%), decreased hemoglobin (78% vs 42%), decreased platelets (63% vs 14%), increased aspartate aminotransferase (52% vs 34%), and increased alanine aminotransferase (43% vs 30%). 

The most common adverse reactions (≥10%) of any grade reported in PALOMA-3 for IBRANCE plus fulvestrant vs placebo plus fulvestrant were neutropenia (83% vs 4%), leukopenia (53% vs 5%), infections (47% vs 31%), fatigue (41% vs 29%), nausea (34% vs 28%), anemia (30% vs 13%), stomatitis (28% vs 13%), diarrhea (24% vs 19%), thrombocytopenia (23% vs 0%), vomiting (19% vs 15%), alopecia (18% vs 6%), rash (17% vs 6%), decreased appetite (16% vs 8%), and pyrexia (13% vs 5%). 

The most frequently reported Grade ≥3 adverse reactions (≥5%) in PALOMA-3 for IBRANCE plus fulvestrant vs placebo plus fulvestrant were neutropenia (66% vs 1%) and leukopenia (31% vs 2%). 

Lab abnormalities of any grade occurring in PALOMA-3 for IBRANCE plus fulvestrant vs placebo plus fulvestrant were decreased WBC (99% vs 26%), decreased neutrophils (96% vs 14%), increased blood creatinine (95% vs 82%), decreased hemoglobin (78% vs 40%), decreased platelets (62% vs 10%), increased aspartate aminotransferase (43% vs 48%), and increased alanine aminotransferase (36% vs 34%). 

Other Clinical Trials Experience: venous thromboembolism has been reported as an adverse reaction following administration of IBRANCE. 

Avoid concurrent use of strong CYP3A inhibitors. If patients must be administered a strong CYP3A inhibitor, reduce the IBRANCE dose to 75 mg. If the strong inhibitor is discontinued, increase the IBRANCE dose (after 3-5 half-lives of the inhibitor) to the dose used prior to the initiation of the strong CYP3A inhibitor. Grapefruit or grapefruit juice may increase plasma concentrations of IBRANCE and should be avoided. Avoid concomitant use of strong CYP3A inducers. The dose of sensitive CYP3A substrates with a narrow therapeutic index may need to be reduced as IBRANCE may increase their exposure. 

For patients with severe hepatic impairment (Child-Pugh class C), the recommended dose of IBRANCE is 75 mg. The pharmacokinetics of IBRANCE have not been studied in patients requiring hemodialysis. 
 
Please see full Prescribing Information for IBRANCE capsules and tablets.
INDICATIONSIBRANCE® (palbociclib) 125 mg capsules and tablets are indicated for the treatment of adult patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer (mBC) in combination with: 
  • an aromatase inhibitor as initial endocrine-based therapy, or 
  • fulvestrant in patients with disease progression following endocrine therapy.
Please see full Prescribing Information for IBRANCE capsules and tablets.